Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1332Carcinoma, Hepatocellular 784Stomach Neoplasms 721Pancreatic Neoplasms 704Colonic Neoplasms 534Rectal Neoplasms 472Esophageal Neoplasms 423Liver Neoplasms 320Neoplasms 264Breast Neoplasms 220Lung Neoplasms 188Gastrointestinal Neoplasms 164Cholangiocarcinoma 150Barrett Esophagus 116Prostatic Neoplasms 107Neoplasm Metastasis 105Ovarian Neoplasms 89Carcinoma, Non-Small-Cell Lung 80Anus Neoplasms 77Melanoma 72Esophageal Squamous Cell Carcinoma 71Head and Neck Neoplasms 70Disease 70Gastrointestinal Stromal Tumors 67Colorectal Neoplasms, Hereditary Nonpolyposis 67Biliary Tract Neoplasms 67Liver Cirrhosis 60Gallbladder Neoplasms 58Recurrence 57Uterine Cervical Neoplasms 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Restless Legs Syndrome × Gastrointestinal × Clear all
NCT01138124 2017-05-30

Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)

GlaxoSmithKline

Completed
54,202 enrolled 21 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Diabetes Mellitus, Epilepsy, Hypertension, Kidney Neoplasms, Neuralgia, Pancreatic Neoplasms, Restless Legs Syndrome, Pancreatitis, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡